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SUMMARY 
 
We describe a patient in whom long-term, therapeutic infusion of the selective gamma-
amino-butyric acid type B (GABAB) receptor agonist, baclofen, into the cerebrospinal fluid 
gave rise to three distinct varieties of memory impairment: i) repeated, short periods of severe 
global amnesia, ii) accelerated long-term forgetting, evident over intervals of days and iii) a 
loss of established autobiographical memories. This pattern of impairment has been reported 
in patients with temporal lobe epilepsy, in particular the subtype of Transient Epileptic 
Amnesia. The amnesic episodes and accelerated forgetting remitted on withdrawal of 
baclofen, while the autobiographical amnesia persisted. This exceptional case highlights the 
occurrence of ‘non-standard’ forms of human amnesia, reflecting the biological complexity 
of memory processes. It suggests a role for GABAB signalling in the modulation of human 
memory over multiple time-scales and hints at its involvement in ‘epileptic amnesia’.  
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1. Introduction  
The complexity of the biochemical, cellular and network mechanisms implicated by 
neuroscience in memory processing predicts corresponding forms of human memory 
disorder. These are likely to defy the monolithic concept of ‘long-term memory’ familiar 
from classical psychology. Examples have recently come to light in studies of patients with 
the most common form of adult-onset epilepsy, temporal lobe epilepsy (TLE), particularly 
the subtype known as transient epileptic amnesia (TEA) (Zeman & Butler, 2010). Patients 
with TEA typically present with a triad of non-standard memory impairments: i) repeated, 
short periods of severe global amnesia, ii) persistent accelerated long-term forgetting (ALF) – 
the loss of newly acquired, initially accessible, memories over hours to weeks, and iii) a 
permanent loss of remote, established, autobiographical memories. Here, we report a detailed 
study of a patient who developed precisely this pattern of memory impairment in the context 
of therapeutic infusion of baclofen, a selective agonist at the GABAB receptor, into the 
cerebrospinal fluid (CSF).  
 
Baclofen is a widely-used therapy for ‘spasticity’, the increase in muscle tone and tendon 
reflexes, sometimes accompanied by painful spasms, which can result from lesions of the 
descending corticospinal tracts. It can be given orally, or, in more severe cases, by infusion 
from an implanted pump into the CSF (Hsieh & Penn, 2006). This targets the drug on the 
desired spinal site of action, but the normal bulk flow of CSF toward the brain sometimes 
leads to CNS side-effects (Kofler, Kronenberg, Rifici, Saltuari, & Bauer, 1994). In overdose, 
intrathecal baclofen can cause coma and status epilepticus (Nugent, Katz, & Little, 1986; 
Saltuari, Marosi, Kofler, & Bauer, 1992). Memory disturbance has been described 
occasionally in patients taking baclofen (Sandyk & Gillman, 1985), including reports, with 
very limited neuropsychological detail, of two patients with discrete, recurrent episodes of 
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memory loss in the context of intrathecal baclofen treatment (Grande, Loeser, & Samii, 2008; 
Rosenblum & Desan, 2014) This association between baclofen and memory impairment is in 
keeping with the crucial role of the GABAB receptor, at which baclofen is a selective agonist, 
in memory processing (Gassmann & Bettler, 2012). 
 
GABA, the main inhibitory neurotransmitter in the human nervous system, acts at both 
ionotropic (GABAA) and metabotropic (GABAB) receptors. In the context of memory, close 
interactions between GABAB receptors and the glutamatergic system, involving pre- and 
post-synaptic effects, maintain a favourable ‘dynamic range’ for memory processing at 
synapses in the hippocampus and neocortex. The GABAB receptor has been implicated in 
both the short and longer term control of memory, through effects on early and late synaptic 
events: the former include early phases of long-term potentiation and depression (Davies, 
Starkey, Pozza, & Collingridge, 1991), the latter processes of synaptic growth and retraction 
involving crucial regulatory proteins such as cyclic adenosine monophosphate response 
element-binding protein (CREB) (White et al., 2000) and brain-derived neurotrophic factor 
(BDNF) (Khundakar & Zetterstrom, 2011). Activation of the GABAB receptor in 
experimental studies in animals has predominantly, though not exclusively, inhibitory effects 
on memory processing (Gassmann & Bettler, 2012).  
 
Although the combination of epilepsy and memory disturbance has been described in the 
recently recognised syndrome of limbic encephalitis associated with antibodies to the 
GABAB receptor (Lancaster et al., 2010), we did not suspect a link between GABA signalling 
and the features of TEA until we were contacted by MK and CS. Encountering our project 
website (http://projects.exeter.ac.uk/time/), they were struck by the similarities between CS’ 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5 
 
symptoms and those described in TEA. We conducted a series of tailored experiments ON 
baclofen and OFF baclofen to explore the nature of CS’ amnesia under controlled conditions.  
 
2. Methods 
2.1 Participants 
In Experiments 1-3, control participants were healthy individuals (1m/8f) matched for age 
and education with CS (see supplementary data for full details of basic psychometric data and 
Methods). There were no significant differences between CS and control participants on 
standard measures of intelligence (Wechsler Abbreviated Scale of Intelligence Scale (WASI) 
similarities, matrix reasoning), visual memory (Rey figure delayed recall), or executive 
function (verbal fluency) either ON or OFF baclofen. There was a trend toward a reduction in 
delayed story recall (p = 0.09) in CS when tested ON baclofen. CS’ depression rating on the 
Hospital Anxiety and Depression Scale (HADS) was elevated at the time of testing ON 
baclofen  (p<0.002). In Experiment 4, CS’ scores were compared to those obtained from 12 
healthy, age and IQ matched control participants whom we have previously reported (Milton 
et al., 2010). There were no significant differences between CS and these control participants 
on standard measures of verbal memory (immediate and delayed story recall), visual memory 
(Rey figure delayed recall), or executive function (verbal fluency) either ON or OFF 
baclofen. There was a trend toward an elevation of anxiety in CS when tested ON baclofen (p 
= 0.062). Her depression rating on the HADS was elevated both ON and OFF baclofen (p = 
0.002 ON, 0.020 OFF). Informed consent was obtained from all participants with approval by 
appropriate Ethics Committees. 
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2.2 Experiments 
CS had no episodes of transient amnesia during the two week-long periods of testing 
described below.  
 
2.2.1  Experiment 1: word list recall and recognition  
We probed CS’ verbal memory ON and OFF baclofen using four categorical 16-word lists, 
entitled “Animals”, “City”, “Nature” and “Groceries” (Hoefeijzers, Dewar, Della, Butler, & 
Zeman, 2014). Two were used ON baclofen and two OFF baclofen. Controls were tested at 
the same inter-test interval (~ one year). Two learning trials were given of each visually-
presented list, with recall immediately after each trial, at 30 minutes and at one week. 
Recognition was assessed following free recall at one week, using a 64-item yes/no test, 
comprising the 32 target words and 32 foils.  
 
2.2.2  Experiment 2: visual recognition memory 
We probed CS visual memory using 400 complex colour photos (sourced from Getty Images) 
depicting everyday-life scenes and activities(Dewar, Hoefeijzers, Zeman, Butler, & Della 
Sala, 2015). 200 were used for the ON baclofen test, the remaining 200 for the OFF baclofen 
test. Different subsets of stimuli were probed after 30 min and 1 week. Controls were tested 
at the same interval as CS. On each occasion, 120 pictures were studied sequentially for 4 
seconds each. Recognition memory was tested at 30 minutes and I week using 40 photos 
from the original 120 photos (i.e. targets), 20 photos closely resembling 20 of the original 
photos (i.e. similar foils) and 20 dissimilar foils. 
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2.2.3  Experiment 3: incidental learning  
The experimenter told an apparently casual but well-rehearsed story during a prearranged 
interval in testing. This consisted of 51 story points. Retention was probed without warning 
one week later, first via free recall, followed by a 5-alternative forced-choice recognition test, 
consisting of 13 questions. We used the same story ON and OFF baclofen. 
 
2.2.4 Experiment 4: autobiographical memory  
We investigated CS’ autobiographical memory using an exacting measure designed to 
distinguish the ‘episodic’ or ‘internal’ details which are evoked when we re-experience past 
events, relating to action, place, time, perception, thought and emotion, from ‘semantic’ or 
‘external’ details(Levine, Svoboda, Hay, Winocur, & Moscovitch, 2002). ON baclofen, CS 
retrieved a unique autobiographical memory from each decade of her life. General and 
specific probes were used to elicit all available details. OFF baclofen (~ 1 year later) CS 
retrieved the memories volunteered at the first session (‘repeated’ memories), and a new 
memory from each decade (‘new’ memories). The memories were audio-recorded, 
transcribed and scored using standard procedures(Levine et al., 2002).  
 
2.3  Statistical analysis 
Percentage retention scores, hit and false alarm (FA) rates and d-prime (d’) scores were 
calculated using standard methods (see supplementary data). We used Crawford’s modified t-
tests for single case studies (singlims (Crawford & Garthwaite, 2002); RSDT (Crawford & 
Garthwaite, 2005)) to compare CS’ scores and her change in performance from ON to OFF 
baclofen with equivalent values in controls. T-tests were two tailed apart from the ON 
baclofen 1-week t-tests for free recall and autobiographical memory for which we had a 
directional prediction, based on CS’s specific report. 
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3 RESULTS 
  
3.1 Case report   
 
CS, a University educated, 52 year old, female, business executive, developed pain from 
spinal scoliosis in 2005. She underwent initial surgical procedures in 2006 and 2008. During 
a third procedure in 2009 she suffered an incomplete spinal cord injury which left her 
paralysed from the chest down. Apart from her scoliosis, CS had no history of previous 
hospital admissions, chronic disorders, unexplained symptoms or surgery. There was no past 
history of psychological distress or psychiatric disorder. She was a highly independent 
person, had travelled widely in her professional role and enjoyed an active social life. She 
was married, with one child. Following the injury to her spinal cord in 2009, CS developed 
painful and debilitating spasticity affecting her legs and torso. CS became depressed and was 
treated with Sertraline in 2009, to good effect. She continued to take this drug, at a dose of 
100-150 mgs/day, throughout the period described below. An intrathecal baclofen pump was 
inserted in 2010. Control of symptoms required an increasing dose. During the second quarter 
of 2011, on a rising dose of baclofen (Figure 1), CS noted a deterioration of her previously 
excellent memory, as attested by her family and friends. In particular, she found that newly-
formed memories faded rapidly over days to weeks. This ‘delayed’ forgetting differs 
markedly from classic anterograde amnesia, characterised by forgetting of new information 
over seconds. She also found herself unable to ‘re-experience’ remote events, like foreign 
holidays or business trips, which she could previously recollect without difficulty, and it 
became hard to visualise once familiar routes around her neighbourhood. In June 2011, CS 
had the first of many brief amnesic episodes. Lasting from a few minutes to half an hour, 
these were characterised by both difficulty in recalling prior events and in laying down a 
memory for ongoing events. CS had ~30 such episodes while on a high dose of baclofen (see 
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Figure 1). Following dose reduction, they ceased almost completely for around 2 months, but 
after a small increase, they returned. A psychiatrist suggested that they were ‘dissociative’. At 
around this time CS referred herself into our study. Structural MRI scanning of the brain was 
normal. Investigation for epilepsy with standard and sleep deprived EEG recording gave 
negative results. There was no positive response to anticonvulsant treatment with 
Lamotrigine at a near maximal dose of 400 mgs/day. It was discontinued after 6 months. CS 
had a further ~140 episodes of amnesia before withdrawing from baclofen, at our suggestion. 
Following this, the amnesic episodes and ALF stopped altogether. She has since resumed 
low-dose baclofen therapy without recurrence of her amnesic episodes or symptoms of ALF, 
though her remote memory impairment has persisted.  
 
3.2  Experiment 1: word list recall and recognition  
CS’ immediate recall, learning rate and percentage retention at 30-min free recall were 
similar to those of the controls ON and OFF baclofen (Figures 2a,b, c: all p > .123). In 
contrast, her percentage retention at 1-week free recall was impaired ON baclofen (p = .028) 
but not OFF baclofen (p = .276 – Figures 2c,d). Relative to the controls, CS had severe ALF 
ON (p = .004) but not OFF baclofen (p = .544).  Her improvement in 1-week word retention 
from ON to OFF baclofen was significantly larger than the change in performance over the 
equivalent time period in controls (p = .021). Her 1-week word recognition (d’ score – Figure 
3) was marginally reduced ON baclofen (p = .065) but not OFF baclofen (p = .891: see 
supplementary data for a full statement of the results). This reduction was attributable to an 
elevated FA rate ON baclofen (p=.019).  
 
3.3 Experiment 2: visual recognition memory  
Figure 4 shows recognition performance for real-life photos after 30 min and 1 week in CS 
and controls. ON baclofen, CS had a significantly elevated rate of FAs after the 30-min delay 
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(p = .023) and after the 1-week delay (p = .041). Her d’ score was below that of the poorest 
performing control after both delays, with a trend towards statistical significance (30 min: p = 
0.1; 1 week: p = .076). CS’ overall picture recognition performance OFF baclofen was 
comparable to that of the controls, although her FA rate continued to be mildly raised after 
the 1-week delay (p = .083). The improvement in her 1-week picture recognition d’ from ON 
to OFF baclofen was larger than the change in d’ over the equivalent time period in controls, 
(p = .062). CS had no difficulty in discriminating between perceptually similar photos after a 
short delay (900ms), either ON or OFF baclofen (see supplementary data).  
 
3.4 Experiment 3: incidental learning  
CS’ 1-week memory of the story was marginally impaired ON baclofen (Figure 5: free recall: 
p = .066; forced choice recognition: p = .061). OFF baclofen, her memory of the story was 
similar to that of the controls (p=.566 for recall, .598 for recognition; Figure 5b). CS’s 
improvement in recognition memory performance from ON to OFF baclofen was marginally 
larger than the change in performance over the equivalent time period in controls (p = .063).  
 
3.5 Experiment 4: autobiographical memory  
ON baclofen, CS had a lower overall autobiographical memory quality than controls (p < 
.001). Memory was impaired for four of the six decades of her past life, sparing her thirties 
and the most recent decade (Figure 6a,b). The recent, spared, memory concerned her 50th 
birthday celebration, four months before the test session. OFF baclofen, overall memory 
quality was reduced across the life-span, both for ‘repeated’ and ‘new’ memories (both p < 
.001: Figure 6c,d). On this occasion she also supplied a lower mean number of internal details 
(p = .033). The rich memory of her birthday party had degraded markedly, a rare, prospective 
demonstration of ‘retroactive’ loss of a well-established memory.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
11 
 
 
4 Discussion  
4.1  Main findings 
These findings suggest that the GABAB agonist, baclofen, can induce a distinctive and 
unusual pattern of memory impairment, including recurrent episodes of profound, transient 
amnesia, ALF, an early deficit of visual recognition memory and autobiographical amnesia 
(AbA). Remarkably, this is precisely the pattern of memory impairment recently reported in 
the syndrome of TEA (Zeman, Butler, Muhlert, & Milton, 2013; Hoefeijzers et al., 2014; 
Dewar et al., 2014; Milton et al., 2010). In CS’s case the transient memory impairment and 
ALF resolved with withdrawal of baclofen, while her AbA has persisted.  
 
4.2 What caused the episodes of transient amnesia? 
Transient amnesia is a common neurological symptom (Bartsch & Butler, 2013). Its 
differential diagnosis includes post-traumatic, transient global (TGA), transient epileptic, 
transient ischaemic, psychogenic, migrainous and drug-induced variants (see Table 1). 
Although the link between CS’ baclofen treatment and her transient amnesic episodes is 
clear, the mechanism by which baclofen caused them is not. Two previous case reports have 
assumed that baclofen can cause TGA (Grande et al., 2008; Rosenblum & Desan, 2014). This 
is possible, though the brevity and frequency of episodes in these cases would be unusual for 
TGA (Bartsch & Butler, 2013). Baclofen is capable of provoking both generalised and focal 
seizures, making an epileptic mechanism plausible (Han, Cortez, & Snead, 2012; Kofler et 
al., 1994). The lack of associated symptoms of epilepsy, EEG abnormalities or response to 
anticonvulsant treatment, argue somewhat against this diagnosis in CS’ case. We discuss the 
analogies between CS’ case and the features of TEA further below.  
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4.3 The neural basis of ALF  
Between her frequent episodes of transient amnesia, CS’ memories showed a conspicuous 
tendency to fade over days, as documented by our word recall results ON baclofen (see 
Figure 2). This was not caused by the amnesic episodes per se: the marked impairment of 
verbal recall one week occurred in the absence of any discrete amnesic events.  
 
ALF, the accelerated loss over longer intervals of information which can be retrieved 
normally over standard intervals, has been described most often in patients with temporal 
lobe epilepsy, especially transient epileptic amnesia (Elliott, Isaac, & Muhlert, 2014). The 
occurrence of ALF, in any context, raises two key theoretical questions. First, does it result 
from a fragility of the initial memory trace, which only becomes apparent after a delay, or 
from an impairment of memory consolidation? We suspect that in CS’s case, and probably in 
patients with epilepsy as well, both are relevant. While CS’ subjective complaint was of 
fading of memories over days, as documented using our test of verbal recall, there was also 
evidence, from our demanding measure of visual recognition memory, for subtle impairment 
of memory over shorter intervals (see Figure 4). Recent evidence from animal studies points 
to a key role for GABAB signalling in the maintenance and consolidation of memories over 
delays (Cullen, Dulka, Ortiz, Riccio, & Jasnow, 2014) via mechanisms including sharp wave-
ripples (Hollnagel, Maslarova, Haq, & Heinemann, 2014),  immediate-early gene expression 
(Terunuma et al., 2014) and, possibly, neurogenesis (Giachino et al., 2014).   The likelihood 
that ‘recurrent rounds of consolidation-like events’  (Bekinschtein et al., 2007, p261) are 
required to maintain memory traces in the hippocampus predicts a progressive weakening of 
memories in the presence of an agent, such as baclofen, that reduces the effectiveness of each 
iteration.  
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The second key theoretical question is whether ALF results from a structural pathology of the 
episodic memory system or can be caused by a purely physiological – and therefore fully 
reversible – disturbance.  There have been reports of improvement or resolution of ALF on 
treatment of seizures (Midorikawa & Kawamura, 2007; O'Connor, Sieggreen, Ahern, 
Schomer, & Mesulam, 1997), supporting a physiological explanation, but ALF often persists 
in patients whose clinical seizures have ceased (Butler et al., 2007). CS’s case shows 
unequivocally that a fully reversible, pharmacological, effect is capable of causing ALF.  
 
While the effect of baclofen was evidently reversible, we cannot be certain of the anatomical 
site primarily involved. The hippocampus is a plausible candidate, given its high density of 
GABAB receptors (Osten, Wisden, & Sprengel, 2007), proximity to the CSF and involvement 
in TEA (Butler et al., 2013) and related disorders. However other structures, such as the 
septal nuclei (Moor, DeBoer, & Westerink, 1998; Turi, Wittmann, Lechan, & Losonczy, 
2015) and thalamus (Tu, Miller, Piguet, & Hornberger, 2014), could also have played a role.  
 
4.4 The neural basis of autobiographical amnesia 
In contrast to the reversibility of CS’ ALF, her AbA has persisted. A similar dissociation has 
been described in a patient with TEA(Midorikawa & Kawamura, 2007). Taken together, 
these findings suggest that factors giving rise to repeated episodes of transient amnesia can 
render previously established memories persistently inaccessible or delete them altogether. 
The prospective demonstration of such a ‘vanishing memory’ in the case of CS’ 50th birthday 
memory is striking.  
 
Examples of selective or ‘disproportionate’ AbA, due to brain disease, in patients with 
preserved anterograde memory at standard delays, are rare and sometimes controversial 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
14 
 
(Kopelman MD, 2004; Markowitsch & Staniloiu, 2013), but there are other well documented 
examples. Such cases suggest that selective Aba can arise from a range of different 
pathologies, including i) diffuse pathology (Evans JJ, Breen EK, Antoun N, & Hodges JR, 
1996; Evans, Graham, Pratt, & Hodges, 2003), ii) right temporofrontal pathology (Levine B 
et al., 1998; Levine, Svoboda, Turner, Mandic, & Mackey, 2009), iii) visual cortical 
pathology (Rubin & Greenberg, 1998), iv) temporal lobe epilepsy (Tramoni et al., 2011; 
Jansari, Davis, McGibbon, Firminger, & Kapur, 2010; Hornberger et al., 2010; Butler et al., 
2007) as well as v) functional or dissociative amnesia (Staniloiu & Markowitsch H, 2014; 
Markowitsch & Staniloiu, 2013) and the recently described syndrome of ‘severely deficient 
autobiographical amnesia in healthy adults’ (Palombo, Alain, Soderlund, Khuu, & Levine, 
2015). This wide range of potential causes might be predicted from the existence of a 
complex network subserving autobiographical memory (Svoboda, McKinnon, & Levine, 
2006). While the possibility of dissociative amnesia, considered further below, clearly 
deserves consideration in a case such as CS’, with marked autobiographical amnesia and a 
degree of mood disturbance, the growing understanding of the range of neurological causes 
for Aba has enlarged the differential diagnosis (Staniloiu & Markowitsch H, 2014).    
 
4.5 Analogies with transient epileptic amnesia 
The close similarities between the memory disorders induced in CS by baclofen and the 
clinical phenotype of TEA raise the possibility that disturbances in GABAB signalling are 
involved in TEA. Shared features include the episodes of dense transient amnesia, 
background of persistent ALF, lasting, remote AbA and visual recognition memory 
impairment (Dewar et al., 2015; Zeman & Butler, 2010). In particular, CS’ case suggests the 
testable hypothesis that ALF in TEA might be due to an up-regulation of GABAB signalling. 
Altered expression of GABAB receptors has been described in the hippocampus of patients 
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with TLE (Furtinger, Pirker, Czech, Baumgartner, & Sperk, 2003; Munoz, Arellano, & 
DeFelipe, 2002) and GABAB receptors are functionally upregulated in epilepsy-prone 
lethargic (Ih/Ih) mice(Hosford et al., 1992).  
 
4.6  The possibility of ‘psychogenic amnesia’ 
Several features of CS’ case might raise suspicion of a ‘psychogenic’, ‘dissociative’ or 
‘functional’ form of amnesia (see Table 1). Functional amnesia classically affects 
autobiographical memory and has been described as a rare cause of ALF (Markowitsch & 
Staniloiu, 2013; Staniloiu & Markowitsch H, 2014). Her spinal cord injury was a severely 
stressful life event.  In its aftermath she became depressed and was treated with an 
antidepressant, Sertraline.  When tested ON baclofen, while CS no longer satisfied criteria for 
major depression, her HADS score (12) placed her just within the abnormal range (11-21 – 
although this score was probably inflated by her neurological symptoms).  
 
However, CS’s case fully satisfies only one of the six criteria suggested by Markowitsch and 
Staniloiu (Markowitsch & Staniloiu, 2013) as supportive of a diagnosis of ‘functional 
retrograde amnesia’, namely the relationship of the onset to psychological trauma or stress. 
The other criteria comprise:  i) selective retrograde amnesia, ii) loss of personal identity, iii) 
absence of a physical or medical cause for amnesia; iv) prior history of psychological trauma 
or mood disorder; v) belle indifference. With the partial exception of CS’ recent, successfully 
treated, reactive depression, her case does not satisfy these five criteria. The absence of these 
features, together with the distinctive pattern of CS’ amnesia (see 4.5), and the resolution of 
her amnestic episodes and ALF on withdrawal of baclofen, argue strongly for a 
pharmacological rather than a psychological explanation for her memory symptoms.  
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4.7  Pharmacological complexity  
CS’ complex amnesic syndrome developed on treatment with an increasing dose of baclofen 
and resolved once baclofen was withdrawn, suggesting a direct relationship. However, 
throughout the period of treatment with baclofen, CS also received the selective serotonin 
reuptake inhibitor (SSRI), sertraline. As this drug was started prior to the onset of her 
amnesic syndrome and withdrawn after it had resolved, sertraline cannot be the primary 
cause. Could it, however, have acted in concert with baclofen? There are well-established 
interactions between serotonin and GABA in the medial temporal lobes. In particular, acute 
treatment with the SSRI paroxetine causes a transient decrease in BDNF gene expression 
which is mediated by GABAB receptors (Khundakar & Zetterstrom, 2011). Prolonged 
treatment with SSRIs, however, appears likely to increase BDNF gene expression, an effect 
which may be relevant to their antidepressant action (Khundakar & Zetterstrom, 2011). Thus, 
while an interaction between baclofen and sertraline may have contributed to CS’ amnesic 
syndrome, the known pharmacology of the SSRIs suggests that this is unlikely. 
 
4.6 Conclusion 
CS’s case demonstrates that intrathecal baclofen, a GABAB receptor agonist, can cause or 
contribute to a transient amnesic syndrome associated with accelerated long-term forgetting  
and autobiographical amnesia. It suggests that GABAB signalling plays a vital role in human 
memory, modulating memory processes over multiple time scales of minutes, days and years, 
that transmission at the GABAB receptor is relevant to syndromes of transient amnesia in 
humans, and that therapies directed at this target deserve consideration.  
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Figure legends 
 
Figure 1 
Baclofen dose (micrograms/day), attack frequency (/month) and Lamotrigine dose (mgs/day) 
in patient CS over time (Feb 2010 – April 2014). 
 
Figure 2 
Experiment 1a: number of words recalled at learning trials 1 and 2 (2a, b), and percentage 
word retention after 30 minutes and 1 week  (2 c, d) ON baclofen and OFF baclofen in CS 
and at equivalent test times (first test and second test) in 9 controls. Bars indicate +/- 1 
standard deviation. 
 
Figure 3 
Experiment 1b: 1-week word recognition performance ON baclofen and OFF baclofen in CS 
and at equivalent test times (first test and second test) in 9 controls. 3a, b show d’, 3c, d hit 
rate and false alarm rate. Bars indicate +/- 1 standard deviation. 
 
Figure 4 
Experiment 2: 30-minute and 1-week picture recognition performance ON baclofen and OFF 
baclofen in CS and at equivalent test times in 9 controls. 4a, b show d’, 4c, d hit rate, 4 e, f  
false alarm rate. Bars indicate +/- 1 standard deviation. 
 
Figure 5 
Experiment 3: 1-week free recall (proportion correct) and 5-alternative forced-choice 
recognition (proportion correct) of an incidentally-encoded ‘everyday life’ story, ON 
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baclofen and OFF baclofen in CS (5a) and at equivalent test times (first test and second test) 
in 8 controls (5b). Bars indicate +/- 1 standard deviation. 
 
Figure 6 
Experiment 4: internal details and overall memory quality ratings for each decade of life, ON 
(6a, b) and OFF baclofen (6c, d) in CS and in 12 control participants. Bars indicate +/- 1 
standard deviation. 
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Table legends 
 
Table 1 
The clinical features of transient amnesic syndromes: Transient Global Amnesia (TGA), 
Transient Epileptic Amnesia (TEA), Transient Ischaemic Amnesia (TIA) and Functional (or 
Dissociative or Psychogenic) Amnesia. 
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Table 1  
 
 
TGA TEA TIA Functional  
Typical age 50+ years 50+ years 50+ years Any age after early 
childhood, typically 
3-4th decades 
Typical Duration 4-6 hours <1 hour Variable  days or months 
Memory 
impairment 
during episode 
Dense 
anterograde 
amnesia; 
variable 
retrograde 
amnesia 
Variable mix of 
anterograde and 
retrograde 
amnesia – may 
later remember 
attack 
Not well 
characterised 
Variable, but often 
dense retrograde 
amnesia (+/- loss of 
personal identity) 
with preserved 
anterograde 
memory 
Other features 
(sometimes 
present) 
Headache, 
nausea 
Olfactory 
hallucinations, 
automatisms, 
brief loss of 
awareness 
Focal 
neurological 
symptoms and 
signs typically 
present, usually 
arising from 
posterior 
circulation 
Other functional 
symptoms and signs 
may be present; 
mood disturbance 
Precipitants Physical (esp 
immersion in 
cold water) 
and 
Waking  - Stressful life 
events, minor head 
injury, mood 
disturbance 
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psychological 
stresses 
Recurrence rate 6-10%  
patients/year  
Around 1 
seizure/month 
prior to 
treatment 
Recognised but 
not well 
characterised 
Can be isolated, 
recurrent or chronic  
Past medical 
history 
+/- migraine No established 
risk factors 
Cerebrovascular 
risk factors 
Prior psychiatric 
illness, prior 
‘organic’ transient 
amnesia, substance 
abuse 
Interictal/postictal 
/post-episode 
memory 
Subtle 
subclinical 
impairment 
may persist 
for days-
months, but 
no permanent 
deficit 
+/- mild 
impairment on 
standard tests; 
accelerated 
long-term 
forgetting, 
autobiographical 
memory loss 
Risk of 
permanent 
memory 
impairment 
from completed 
stroke 
Variable 
Investigations Hippocampal 
high signal 
lesions on 
DTI at 24-72 
hours in most 
patients 
Routine and 
sleep-deprived 
EEG may show 
epileptiform 
discharges 
Neuroimaging 
may show 
evidence of old 
or new 
ischaemic 
change 
Normal structural 
neuroimaging; 
functional imaging 
changes are 
described, 
especially right 
fronto-temporal 
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